Comparative Pharmacology
Head-to-head clinical analysis: BRIVARACETAM versus DEPAKOTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIVARACETAM versus DEPAKOTE.
BRIVARACETAM vs DEPAKOTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A (SV2A) ligand, binding to SV2A with 15- to 30-fold higher affinity than levetiracetam. It modulates neurotransmitter release, reducing neuronal excitability. It also inhibits voltage-gated sodium channels at clinically relevant concentrations.
Increases GABA levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase; also blocks voltage-gated sodium channels and T-type calcium channels.
50 mg orally twice daily, with or without food. May increase to 100 mg twice daily based on tolerability and efficacy. Maximum 200 mg twice daily.
Initial dose 750 mg/day PO in divided doses; increase by 250-500 mg/day every 3-7 days; maintenance dose 1000-2000 mg/day PO divided BID or TID; maximum 60 mg/kg/day.
None Documented
None Documented
Clinical Note
moderateBrivaracetam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Brivaracetam."
Clinical Note
moderateBrivaracetam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Brivaracetam."
Clinical Note
moderateBrivaracetam + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Brivaracetam."
Clinical Note
moderateBrivaracetam + Fluconazole
Terminal elimination half-life is approximately 9 hours in adults with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to about 20-30 hours, requiring dose adjustment.
Terminal: 9-16 hours (mean 12 h); extended with hepatic dysfunction, co-administered enzyme inhibitors, or in elderly.
Approximately 95% of the dose is excreted renally, with about 8-12% as unchanged drug and the remainder as metabolites (primarily by hydrolysis to the carboxylic acid metabolite). Fecal excretion accounts for less than 1%.
Renal: <3% as unchanged drug; >95% as metabolites (glucuronide conjugates, oxidation products). Biliary/fecal: minor, <5%.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Brivaracetam."